TLDR
- IMMP shares plummeted approximately 80% on Friday following the termination of its Phase III trial targeting lung cancer due to futility concerns.
- An Independent Data Monitoring Committee advised discontinuation of the TACTI-004 study testing eftilagimod alfa (efti) for first-line non-small cell lung cancer treatment.
- Baird shifted its rating from Outperform to Neutral while dramatically reducing the price target from $7.00 down to $1.00.
- Citizens followed suit with a downgrade from Market Outperform to Market Perform, eliminating all NSCLC-related revenue forecasts.
- Share volume skyrocketed beyond 11 million shares — dramatically higher than the typical daily average of approximately 154,000 — as panic selling ensued.
Shares of Immutep (IMMP) experienced a devastating decline of roughly 80% on Friday following the biotech company’s announcement that it would discontinue its TACTI-004 Phase III clinical trial. The experimental study had been testing eftilagimod alfa, commonly referred to as “efti,” as a treatment option for patients diagnosed with first-line non-small cell lung cancer (NSCLC).
The decision to terminate the trial stemmed from guidance provided by the Independent Data Monitoring Committee (IDMC), which conducted a thorough analysis of both safety and efficacy metrics before determining the study should cease due to futility. Simply put: the available evidence indicated the therapy would not achieve its intended endpoints even if the trial proceeded to completion.
Chief Executive Officer Marc Voigt expressed clear disappointment with the outcome. “We are very disappointed and surprised with the outcome of the futility analysis, in light of efti’s performance in every other clinical trial,” he acknowledged in an official company statement.
The company confirmed it would immediately cease new patient enrollment and initiate a systematic shutdown of the study, which includes completing patient follow-up procedures and properly closing trial sites according to all regulatory standards.
Wall Street Analysts Slash Forecasts and Recommendations
Investor sentiment turned sharply negative — and equity research analysts wasted no time adjusting their outlook.
Baird’s Colleen Kusy moved her rating on IMMP from Outperform down to Neutral while simultaneously slashing her price objective from $7.00 to just $1.00. With shares trading near $2.76 when the downgrade was published, the stock remained substantially above the revised target. Baird’s assessment concluded there’s no obvious pathway for efti’s success after this setback.
Citizens’ analyst Reni Benjamin similarly lowered his stance, transitioning from Market Outperform to Market Perform. Benjamin completely eliminated all NSCLC-related revenue assumptions from his financial models.
Both research firms anticipate the shares will track broader market performance until substantial data emerges from other ongoing randomized clinical studies.
Prior to Friday’s devastating news, IMMP stock was down roughly 3.5% for the year-to-date period but had posted impressive gains of 55% over the trailing twelve months. Those gains have now been virtually wiped out.
The Road Ahead for Immutep
There is one potential positive development: eliminating the TACTI-004 trial removes a significant expense from the company’s budget. Immutep now projects its available cash reserves will sustain operations substantially beyond the previously communicated Q2 2027 timeline. Management indicated it will provide refined cash guidance once the trial shutdown process reaches completion.
The company emphasized its commitment to advancing other pipeline programs. Nevertheless, given that NSCLC represented the flagship development effort, the company’s strategic options have clearly narrowed.
Friday’s trading activity painted a vivid picture of investor panic. Over 11 million shares traded hands during the morning session alone — a staggering contrast to the three-month average daily volume of approximately 154,000 shares. This represents roughly 70 times normal trading activity.
The current consensus recommendation for IMMP stands at Hold, derived from two Hold ratings. No average price target is currently available for the stock.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
